Syndax Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
SNDX
CUSIP
87164F105
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 87164F105 since 12/18/2024, largest first.

Filer % of Class Filed
Kynam Capital Management, LP 13G/A
10.0% 2/14/2025
Event 12/31/2024
BlackRock, Inc. 13G/A 7.8% 4/17/2025
Event 3/31/2025
Goldman Sachs Group Inc 13G/A
6.5% 8/13/2025
Event 6/30/2025
State Street Corp 13G 6.4% 8/7/2026
Event 6/30/2026
Vanguard Capital Management LLC 13G 5.1% 4/30/2026
Event 3/31/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
Morgan Stanley 13G/A
2.4% 5/7/2025
Event 3/31/2025
Point72 Asset Management, L.P. 13G/A
2.3% 5/15/2026
Event 3/31/2026
Wellington Management Group LLP 13G/A
0% 3/7/2025
Event 2/28/2025
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 5 13.9 k $261 k
2026 Q2 254 110 M $2.46 B
2026 Q1 264 101 M $2.35 B
2025 Q4 252 100 M $2.10 B
2025 Q3 248 101 M $1.56 B
2025 Q2 239 103 M $962 M
2025 Q1 240 101 M $1.26 B
2024 Q4 232 98.0 M $1.30 B
2024 Q3 233 89.6 M $1.73 B
2024 Q2 209 89.2 M $1.83 B
2024 Q1 201 94.6 M $2.25 B
2023 Q4 196 93.5 M $2.02 B
2023 Q3 206 72.6 M $1.05 B
2023 Q2 177 71.0 M $1.49 B
2023 Q1 174 73.5 M $1.55 B
2022 Q4 169 75.5 M $1.92 B
2022 Q3 146 60.0 M $1.44 B
2022 Q2 125 55.2 M $1.06 B
2022 Q1 140 54.6 M $949 M
2021 Q4 147 53.3 M $1.17 B
2021 Q3 129 49.1 M $938 M
2021 Q2 121 50.2 M $862 M
2021 Q1 140 48.8 M $1.12 B
2020 Q4 157 47.4 M $1.06 B
2020 Q3 106 34.2 M $505 M
2020 Q2 109 32.6 M $484 M
2020 Q1 90 20.8 M $228 M
2019 Q4 83 17.0 M $149 M
2019 Q3 79 17.1 M $128 M
2019 Q2 82 17.5 M $163 M
2019 Q1 73 17.0 M $89.1 M
2018 Q4 84 15.7 M $69.7 M
2018 Q3 86 15.5 M $125 M
2018 Q2 92 15.1 M $106 M
2018 Q1 76 17.2 M $245 M
2017 Q4 80 17.2 M $150 M
2017 Q3 68 15.0 M $176 M
2017 Q2 66 15.7 M $219 M
2017 Q1 64 11.8 M $162 M
2016 Q4 58 11.2 M $80.0 M
2016 Q3 45 11.6 M $176 M
2016 Q2 47 10.3 M $102 M
2016 Q1 27 9.44 M $126 M